Erythropoietin treatment and the risk of hip fractures in hemodialysis patients

Erythropoietin (EPO) is the primary regulator of bone marrow erythropoiesis. Mouse models have provided evidence that EPO also promotes bone remodeling and that EPO‐stimulated erythropoiesis is accompanied by bone loss independent of increased red blood cell production. EPO has been used clinically...

Descripción completa

Detalles Bibliográficos
Autores principales: Suresh, Sukanya, Wright, Elizabeth C., Wright, Daniel G., Abbott, Kevin C., Noguchi, Constance T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8360057/
https://www.ncbi.nlm.nih.gov/pubmed/33949002
http://dx.doi.org/10.1002/jbmr.4297

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8360057/
https://www.ncbi.nlm.nih.gov/pubmed/33949002
http://dx.doi.org/10.1002/jbmr.4297

Ejemplares similares